Skip to content
CNS Clinical Research

Cleveland, Ohio

CNS clinical trials in Cleveland, OH

55 CNS studies are recruiting participants at sites in Cleveland as of November 16, 2026, according to ClinicalTrials.gov. CNS Clinical Research can help you understand your options and connect with a study team.

Call (888) 520-7418
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Cleveland at a glance

  • 55 studies are recruiting at a site in Cleveland.
  • By phase: Phase 1 (1), Phase 1/2 (2), Phase 2 (5), Phase 2/3 (1), Phase 3 (12), Phase 4 (5), No phase (16), Observational (13). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (26), university, hospital or other (23), government (6).
  • By research area: Parkinson's Disease (19), Multiple Sclerosis (14), Epilepsy (11), Depression (7), Migraine (2), Bipolar Disorder (1), Schizophrenia (1).
  • Most recent update to one of these records: November 16, 2026.

Depression studies recruiting in Cleveland

Basic details from each study's public record (the 30 most recently updated of 55). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

    • Phase 2
    • Ages 18 to 80
    • All sexes
    Sponsor
    Reunion Neuroscience Inc
    Study site
    Cleveland Clinic
    Registry record
    NCT07002034 · updated
  2. Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

    • No phase
    • Ages 22 to 70
    • All sexes
    Sponsor
    Abbott Medical Devices
    Study site
    The Cleveland Clinic Foundation
    Registry record
    NCT06423430 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Cleveland, OH on ClinicalTrials.gov.

Schizophrenia studies recruiting in Cleveland

  1. REACH Study (Recovery Environments: Assessing Cognitive & Brain Health in Community Mental Health)

    • No phase
    • Ages 18 to 50
    • All sexes
    Sponsor
    Case Western Reserve University
    Study site
    Case Western Reserve University
    Registry record
    NCT07006935 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Cleveland, OH on ClinicalTrials.gov.

Bipolar disorder studies recruiting in Cleveland

  1. Attentional Biases, Reward Sensitivity, and Cognitive Control in Adults With Bipolar Disorder

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    University Hospitals Cleveland Medical Center
    Study site
    University Hospitals Cleveland Medical Center - Mood Disorders Program
    Registry record
    NCT03829787 · updated

Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in Cleveland, OH on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Cleveland

  1. A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

    • Phase 3
    • Ages 50 to 85
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Cleveland Clinic
    Registry record
    NCT07174310 · updated
  2. A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

    • Phase 2
    • Ages 30 to 80
    • All sexes
    Sponsor
    Appello Pharmaceuticals, Inc.
    Study site
    Cleveland Clinic (Site #223)
    Registry record
    NCT07432958 · updated
  3. Genetics and Aerobic Exercise to Slow Parkinson's Disease Trial

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    Jay Alberts
    Study site
    The Cleveland Clinic
    Registry record
    NCT06442033 · updated
  4. Neural Mechanisms of Aerobic Exercise Benefits in PD With DBS

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    The Cleveland Clinic
    Study site
    Cleveland Clinic
    Registry record
    NCT07442747 · updated
  5. Decoding the Neural Mechanisms Underlying Postural Instability and Gait Dysfunction in Parkinson's Disease

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    The Cleveland Clinic
    Study site
    Cleveland Clinic
    Registry record
    NCT07748962 · updated
  6. A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

    • Phase 2/3
    • Ages 40 to 80
    • All sexes
    Sponsor
    Biohaven Therapeutics Ltd.
    Registry record
    NCT06976268 · updated
  7. BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease

    • Phase 4
    • Ages 40 and older
    • All sexes
    Sponsor
    The Cleveland Clinic
    Study site
    Cleveland Clinic
    Registry record
    NCT07138560 · updated
  8. Parkinson's Foundation PD GENEration Genetic Registry

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    Parkinson's Foundation
    Study sites
    Case Western Reserve University · Cleveland Clinic
    Registry record
    NCT04994015 · updated
  9. Deep Brain Stimulation Neural Recordings of Varied Stimulation During Sleep in Parkinson's Disease

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    The Cleveland Clinic
    Study site
    Cleveland Clinic
    Registry record
    NCT07110376 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Cleveland, OH on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Cleveland

  1. Understanding and Enhancing Human Health and Movement

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    Louis Stokes VA Medical Center
    Study site
    Louis Stokes Cleveland VA Medical Center
    Registry record
    NCT07738978 · updated
  2. A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    TG Therapeutics, Inc.
    Study site
    TG Therapeutics Investigational Trial Site
    Registry record
    NCT06433752 · updated
  3. A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    TG Therapeutics, Inc.
    Study site
    TG Therapeutics Investigational Trial Site
    Registry record
    NCT06680037 · updated
  4. Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

    • Phase 3
    • Ages 40 to 70
    • All sexes
    Sponsor
    Novartis Pharmaceuticals
    Study site
    Cleveland Clinic Foundation
    Registry record
    NCT06846281 · updated
  5. Care in Multiple Sclerosis (MS)

    • Observational
    • Ages 18 to 29
    • All sexes
    Sponsor
    NYU Langone Health
    Study site
    Cleveland Clinic
    Registry record
    NCT07011914 · updated
  6. Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    TG Therapeutics, Inc.
    Study site
    TG Therapeutics Investigational Trial Site
    Registry record
    NCT05877963 · updated
  7. Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

    • Phase 3
    • Ages 18 to 55
    • All sexes
    Sponsor
    National Institute of Allergy and Infectious Diseases (NIAID)
    Study site
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic
    Registry record
    NCT04047628 · updated
  8. A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Novartis Pharmaceuticals
    Study site
    Cleveland Clinic Ohio
    Registry record
    NCT07225504 · updated
  9. AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

    • Phase 1/2
    • Ages 18 to 75
    • All sexes
    Sponsor
    UniQure Biopharma B.V.
    Study site
    Cleveland Clinic
    Registry record
    NCT06063850 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Cleveland, OH on ClinicalTrials.gov.

Epilepsy studies recruiting in Cleveland

  1. Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Rapport Therapeutics Inc.
    Registry record
    NCT07563881 · updated
  2. A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Xenon Pharmaceuticals Inc.
    Study site
    Cleveland Clinic Foundation
    Registry record
    NCT05667142 · updated
  3. A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Xenon Pharmaceuticals Inc.
    Study site
    Cleveland Clinic
    Registry record
    NCT05716100 · updated
  4. A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

    • Phase 3
    • Ages 2 and older
    • All sexes
    Sponsor
    Epygenix
    Study site
    Cleveland Clinic
    Registry record
    NCT04462770 · updated
  5. Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up

    • Observational
    • Ages 18 to 75
    • All sexes
    Sponsor
    Epiminder America, Inc.
    Study site
    University Hospitals Cleveland Medical Center
    Registry record
    NCT07110454 · updated
  6. RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Study site
    Neurology Institute Epilepsy Center of Cleveland Clinic
    Registry record
    NCT06798896 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Cleveland, OH on ClinicalTrials.gov.

Migraine studies recruiting in Cleveland

  1. Randomized Study in Children and Adolescents With Migraine: Acute Treatment

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study site
    University Hospitals Cleveland Medical Center
    Registry record
    NCT04649242 · updated
  2. Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study site
    University Hospitals Cleveland Medical Center
    Registry record
    NCT04743141 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Cleveland, OH on ClinicalTrials.gov.

Ask about studies near Cleveland

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Ohio

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 520-7418

or send a short form

How should we reach you?

Call